Concurrent Chemoradiotherapy for Advanced Pancreatic Cancer

Kinji Nishiyama; Masahiko Koizumi; Eiichi Tanaka; Tatsuya Ioka; Hiroyuki Uehara; Hiroyasu Iishi; Akihiko Nakaizumi; Hiroaki Ohigashi; Osamu Ishikawa
June 2007
Strahlentherapie und Onkologie;Jun2007, Vol. 183 Issue 6, p301
Academic Journal
Purpose:  To examine the feasibility of concurrent use of full-dose gemcitabine (GEM) and radiotherapy for advanced pancreatic cancer. Patient and Methods:  22 patients with advanced pancreatic cancer were subjected to concurrent chemoradiotherapy (GEM 1,000 mg/m2 weekly, three times during 4 weeks). They received limited-field irradiation by three-dimensional radiotherapy planning. Results:  Of the 22 patients, 16 (72%) completed the treatment (50 Gy irradiation and at least three times concurrent administration of 1 g/m2 GEM). One patient with unresectable tail cancer showed peritonitis carcinomatosa and both chemotherapy and radiotherapy had to be stopped. Dose reduction or omission of GEM was necessary in another four patients. In addition, radiotherapy was discontinued in one patient for fatigue. Grade 3 hematologic toxicity was detected in eight patients (36%), and grade 3 nonhematologic toxicity (anorexia) in one patient (5%). In total, the response rate amounted to 32% (seven partial responses), and the median survival time (MST) was 16 months. Among the twelve patients who received preoperative chemoradiotherapy, nine underwent surgery and showed a survival rate of 78% at 1 year. Another 13 patients without surgery showed 14 months of MST. No regional lymph node failure has appeared so far. Conclusion:  Limited-field radiotherapy enables the safe concurrent administration of 1,000 mg/m2 GEM.


Related Articles

  • History of Cancer, Ancient and Modern Treatment Methods. Sudhakar, Akulapalli // Journal of Cancer Science & Therapy;Dec2009, Vol. 1 Issue 2, p1 

    The author reflects on the history of cancer and its ancient and modern treatment methods in the U.S. He mentions an overview of cancer as the second leading cause of death worldwide after cardiovascular diseases where half of men and one third of women develop cancer and millions of cancer...

  • Review: various interventions prevent or reduce oral mucositis in patients with cancer receiving chemotherapy or radiotherapy. Sherwood, Paula R. // Evidence Based Nursing;Jan2007, Vol. 10 Issue 1, p13 

    The article reviews a study which tested the effectiveness of interventions for preventing oral mucositis in patients with cancer receiving chemotherapy or radiotherapy. Findings showed a reduction in the incidence or severity of mucositis among the patients following interventions with...

  • Recurrent Syncope in a Cancer Patient: A Case Report and Review of the Literature. Sharma, Jyoti; Dougherty, Anne H. // Cardiology Research & Practice;2011, p1 

    A 59-year-old male with invasive squamous cell carcinoma of the left preauricular region, treated with several chemotherapy regimens and radiation therapy, was admitted for recurrent syncopal episodes. He was found to be suffering from neurocardiogenic reflex-mediated syncope secondary to...

  • Sensorineural hearing loss after concurrent chemoradiotherapy in nasopharyngeal cancer patients. Petsuksiri, Janjira; Sermsree, Achariyaporn; Thephamongkhol, Kullathorn; Keskool, Phawin; Thongyai, Kanthong; Chansilpa, Yaowalak; Pattaranutaporn, Pittayapoom // Radiation Oncology;2011, Vol. 6 Issue 1, p19 

    Background: Sensorineural hearing loss (SNHL) is one of the major long term side effects from radiation therapy (RT) in nasopharyngeal cancer (NPC) patients. This study aims to review the incidences of SNHL when treating with different radiation techniques. The additional objective is to...

  • Correction of patient positioning errors based on in-line cone beam CTs: clinical implementation and first experiences. Thilmann, Christoph; Nill, Simeon; Tücking, Thomas; Höss, Angelika; Hesse, Bernd; Dietrich, Lars; Bendl, Rolf; Rhein, Bernhard; Häring, Peter; Thieke, Christian; Oelfke, Uwe; Debus, Juergen; Huber, Peter // Radiation Oncology;2006, Vol. 1, p16 

    Background: The purpose of the study was the clinical implementation of a kV cone beam CT (CBCT) for setup correction in radiotherapy. Patients and methods: For evaluation of the setup correction workflow, six tumor patients (lung cancer, sacral chordoma, head-and-neck and paraspinal tumor, and...

  • Treatment and survival of patients with small-cell lung cancer: small steps forward, but not for patients >80. Janssen-Heijnen, M. L. G.; Maas, H. A. A. M.; Siesling, S; Koning, C. C. E.; Coebergh, J. W. W.; Groen, H. J. M. // Annals of Oncology;Apr2012, Vol. 23 Issue 4, p954 

    Background: Seventy-five percent of newly diagnosed patients with small-cell lung cancer (SCLC) are aged 60+ and quite a few are treated less aggressively because of fear of toxic effects. We described trends in treatment and survival of unselected SCLC patients. Patients and methods: For the...

  • Magic of Homoepathic Tinctures of Herbs in Breast Tumour. Harris, R. // Journal of Cancer Science & Therapy;2011, Vol. 3 Issue 8, p181 

    The article discusses two case studies including a woman who developed breast cancer after her dog jumped on her and damaged her breast, and a 38-years-old mother with 6 weeks old baby girl by Caesarean section developed class 1 cancer of both ovaries. It notes that both patients underwent...

  • Leaves Patients Warm and Fuzzy.  // ASRT Scanner;Oct/Nov2009, Vol. 42 Issue 1, p50 

    The article reports on the creation and delivery of blankets for cancer patients to use during chemotherapy and radiation treatments by the radiology staff of Lake Regional Health System in Osage Beach, Missouri, in celebration of the National Radiologic Technology Week in November 2009....

  • Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. Bengala, C.; Zamagni, C.; Pedrazzoli, P.; Matteucci, P.; Ballestrero, A.; Da Prada, G.; Martino, M.; Rosti, G.; Danova, M.; Bregni, M.; Jovic, G.; Guarneri, V.; Maur, M.; Conte, P. F. // British Journal of Cancer;4/10/2006, Vol. 94 Issue 7, p1016 

    HER-2 overexpression is associated to a poor prognosis in high-risk and metastatic breast cancer (MBC) patients treated with high-dose chemotherapy (HDC). HER-2 status is also a predictive factor and when trastuzumab is administered in combination with or sequentially to chemotherapy, a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics